Effects of Statin Therapy on Leukocyte Telomere Length, an Anti-Aging Biomarker: A Systematic Review and Meta-analysis Group IV
Nicole Alexandria Guevara, MD, Emilio Jose Gravador, MD, Dandie De Mesa, MD
Eleazar Suguitan, MD, Wilbur Jan Robert Demafiles, MD, Jessa Mae Tan, MD & Dianne Ruedas, MD
Maria Luz Joana B. Soria, MD*
Objective: Leukocyte Telomere Length (LTL) is an emerging anti-aging biomarker and has been suggested to have an association with statin therapy. This study aims to determine the effects of statin therapy on LTL.
Methodology: An electronic search of articles published in the English language in the last 10 years (2006-2016) was done. Participants were statin (any statin dose, frequency, and type) versus non-statin users wherein LTL from peripheral white blood cells was measured in kilobase. This study excluded telomere syndromes and connective tissue diseases. Data was analyzed using continuous data analysis and random effects model. Mean difference was computed at 95% confidence interval (p ≤ 0.05 as statistically significant). Heterogeneity was determined (I2 where > 50% = significantly heterogenous).
Results: Two studies involving 508 participants (163 statin users versus 345 non-statin users) were found to be eligible. Both studies showed a direct relationship between statin therapy and LTL. Statin users showed longer LTL compared to non-statin users (6.04 +/- 0.04kb and 1.29 +/- 0.11kb in statin users versus 5.96 +/- 0.04 and 1.25 +/- 0.11 for non-statin). However, these results are not statistically significant (p= 0.06)
Conclusion: This meta-analysis demonstrates a non-statistically significant relationship between LTL and statin therapy.
Keywords: Statin, HMG-CoA reductase inhibitor, anti-aging, leukocyte telomere length, telomere length
*Adviser/Consultant, Department of Internal Medicine